Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

Shareholders woke up to the idea that their company will have a new owner by the end of the year.

Simulations Plus (SLP) has entered into a definitive agreement to be acquired by affiliates of Altaris for $375 in an all-cash transaction. Under the terms of the agreement, Simulations Plus common ...

After the deal closes, expected in the fourth quarter of this year, Altaris plans to combine Simulations Plus with its existing portfolio company, Chemical Computing Group, which ...

Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and ...

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

CEO Shawn O’Connor highlighted a 23% year-over-year revenue increase, with 5% organic growth, driven by the Adaptive Learning & Insights (ALI) and Medical Communication (MC) business units. Adjusted ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Medical tech company Simulations Plus (NASDAQ: SLP) ended up slightly in positive territory on Friday. That was largely due to solid quarterly results, although a bottom-line guidance cut dampened ...

Simulations Plus, Inc., a Durham-based global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, entered into a definitive agreement to be acquired by ...